Completed PHASE1 INTERVENTIONAL NCT00000737
A Phase I/II Study to Evaluate Single Agent and Combination Therapy With Megestrol Acetate and Dronabinol for the Treatment of HIV-Wasting Syndrome
Sponsor: Bristol-Myers Squibb
Conditions
Cachexia HIV Infections HIV Wasting Syndrome
Interventions
Dronabinol Megestrol acetate
Updated 5 times since 2017 Last updated: Aug 22, 2008
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
Listed as NCT00000737, this PHASE1 trial focuses on Cachexia and HIV Infections and remains completed. Sponsored by Bristol-Myers Squibb, it has been updated 5 times since 2026, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Bristol-Myers Squibb
- National Institute of Allergy and Infectious Diseases (NIAID)
- Roxane Laboratories
Data source: National Institute of Allergy and Infectious Diseases (NIAID)
For direct contact, visit the study record on ClinicalTrials.gov .